Search

Search Constraints

You searched for: Record Type Journal Article Author/Creator Mittal, Deepak

Search Results

2. CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity. (4th May 2018)

3. CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer. Issue 9 (14th August 2018)

5. Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. (3rd July 2018)

6. HPV16 E7 expression in skin induces TSLP secretion, type 2 ILC infiltration and atopic dermatitis‐like lesions. Issue 6 (20th January 2015)

9. The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor‐infiltrating T cells. Issue 2 (17th October 2018)

10. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti‐PD‐L1 antibody for treatment of triple‐negative breast cancer. Issue 1 (31st May 2019)